Search Results

Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children with one or more food allergies.

Recent decisions to reduce health and science research funding and limit the participation of international students and researchers could prove damaging in the short and long term.

Intrommune Therapeutics, Inc., a biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, announces data in a late-breaking poster presentation at this year’s American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting in Washington, D.C. supporting Oral Mucosal Immunotherapy as a potential new form of food allergy treatment.

Approved earlier this month for children and adults with one or more food allergies, Xolair in a Phase III study reduced severe allergic reactions in patients suffering from multiple food allergies.